<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00338780</url>
  </required_header>
  <id_info>
    <org_study_id>NUC30934</org_study_id>
    <nct_id>NCT00338780</nct_id>
  </id_info>
  <brief_title>Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)</brief_title>
  <official_title>A Randomised, Double-Blinded, Placebo-Controlled Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <brief_summary>
    <textblock>
      The aim is to investigate whether Lamivudine 100mg daily is effective in the long term
      treatment of HBeAg negative chronic HBV infected patients with active liver disease in Asia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent studies have proved lamivudine a very potent antiviral drug in suppressing viral
      replication and improving hepatic necro-inflammation with minimal adverse effects in HBeAg
      positive chronic hepatitis B patients. The efficacy of lamivudine in HBeAg positivce Asian
      patients has been weel established. However, the evidence in HBeAg negative patients is
      limited.

      In the absence of HBeAg seroconversion, guidance on the clinical management of HBeAg negative
      hepatitis B patitents treated with lamivudine and data on the efficacy of lamivudine in
      controlling pre-core HBV disease long-term is still needed. Existing data in HBeAg negative/
      HBV DNA positive HBV demonstrate clear and statisticallysignificant serological benefit of
      lamivudine over placebo during treatment. Limited sustained response was observed
      post-treatment following a one year treatment period. Whether these results can be applied to
      patients in Asia is uncertain. This study is therefore intended to further assess te efficacy
      profile over an extended treatment period in the Asian population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date>January 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with complete response (normalisation of LAT, ie. &lt;1xULN and disappearance of HBV DNA, lower limit of detection), at MOnth 24</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with partial response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological improvement at month 24</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with complete response post-treatment (at Month 30)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patinets with partial response post-treatment (at Month 30)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of fibrosis</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of fibrosis to cirrhosis</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg seroconversion</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of treatment</measure>
  </secondary_outcome>
  <condition>Chronic Hepatitis B</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine/ Placebo 100mg daily</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age=&gt;18 years

          -  HBsAg positive and HBeAg negative for at least 6 months prior to screening

          -  Serum HBV-DNA postiviet, HBeAg negative and HBeAb positive at the same timepoint on at
             least one occasion during the last 6 months

          -  ALT &gt;1.5 to 10 x upper limit of normal for at least two occasions within the previous
             6 months and at screening, or ALT &gt; upper limit normal and with at least one
             biochemical flare-up (ALT &gt; 200IU/l) in the last 12 months.

          -  Informed writted consent

          -  Liver biopsy material/ slides taken within the previous 12 months, and at least 5
             months after any previous antiviral treatment which show evidence of active liver
             disease (ie. evidence of necroinflammatory activity)

          -  Written informed consent

        Exclusion Criteria:

          -  Hepatocellular carcinoma

          -  ALT &gt; 10xULN at screening or history of acute exacerbation leading to transient
             decompensation

          -  Serum hepatitis C, hepatitis D or HIV

          -  Decompensated liver desease as indicated by any of the following: serum bilirubin
             &gt;3mg/dL, prothrombin time &gt;=2 seconds prolonged above upper limit of reference range,
             serum albumin &lt;28g/L, history of variceal haemorrhage, presence of intractable ascites
             at the screening assessment.

          -  Encepalopathy

          -  Planned for liver transplantation or previous liver transplantation

          -  Evidence of autoimmune hepatitis

          -  Amylase and/ or lipase &gt; 2 times upper limit of reference range

          -  Serum creatinine &gt;1.5 times upper limit of reference range

          -  Haemoglobin &lt; 11g/dL

          -  WBC count &lt;3x10^9/L

          -  Platelets &lt;100x10^9

          -  Serious concurrent medical illness other than hepatitis B

          -  Use of immunosuppressive therapy, immunomodylatory therapy or chronic antiviral
             thgerpay with other agents within the previous 6 months or during the study

          -  Previous treatment with lamivudine or famciclovir within the last 6 months

          -  History of hypersensitivity to nucleoside analogues

          -  Women of childbearing potential not practising adequate contraception

          -  Pregnancy or lactation

          -  Receipt of any investigational drug within 30 days of the first dose of study drug

          -  Child-Pugh class B or C cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph JY Sung, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong SAR</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 1999 Mar;29(3):889-96.</citation>
    <PMID>10051494</PMID>
  </reference>
  <reference>
    <citation>Maynard JE. Hepatitis B: global importance and need for control. Vaccine. 1990 Mar;8 Suppl:S18-20; discussion S21-3. Review.</citation>
    <PMID>2139281</PMID>
  </reference>
  <reference>
    <citation>Tu H, Xiong SD, Trepo C, Wen YM. Frequency of hepatitis B virus e-minus mutants varies among patients from different areas of China. J Med Virol. 1997 Feb;51(2):85-9.</citation>
    <PMID>9021537</PMID>
  </reference>
  <reference>
    <citation>Tu H, Li PY, Wen YM. Anti-HBe titre in patients infected with wild-type and e-minus variant of hepatitis B virus. Res Virol. 1996 Jan-Feb;147(1):39-43.</citation>
    <PMID>8882339</PMID>
  </reference>
  <reference>
    <citation>ter Borg F, ten Kate FJ, Cuypers HT, Leentvaar-Kuijpers A, Oosting J, Wertheim-van Dillen PM, Honkoop P, Rasch MC, de Man RA, van Hattum J, Chamuleau RA, Reesink HW, Jones EA. Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen. Lancet. 1998 Jun 27;351(9120):1914-8. Erratum in: Lancet 1999 Jul 17;354(9174):258. Lancet 1998 Jul 25;352(9124):328.</citation>
    <PMID>9654258</PMID>
  </reference>
  <reference>
    <citation>Brunetto MR, Giarin MM, Oliveri F, Chiaberge E, Baldi M, Alfarano A, Serra A, Saracco G, Verme G, Will H, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4186-90.</citation>
    <PMID>2034663</PMID>
  </reference>
  <reference>
    <citation>Chu CM, Yeh CT, Chiu CT, Sheen IS, Liaw YF. Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic. J Clin Microbiol. 1996 Jul;34(7):1815-8.</citation>
    <PMID>8784599</PMID>
  </reference>
  <reference>
    <citation>Chan HLY, Hui Y, Ching JYL, Leung NWY, Chan FKL, Sung JJY. Can we predict disease activity in chronic hepatitis B virus (CHB) infected patients with negative HBeAg. Gastroenterology 1999; 116: A1195</citation>
  </reference>
  <reference>
    <citation>Chan HLY,Ghany MC, Lok ASF. Hepatitis B. In Schiff ER, Sorrell MF, Madrey WC, Eds. Schiff's Deseases of the LIver, 8th ed. Lippincott-Raven Publishers, New York, 1998:757-92</citation>
  </reference>
  <reference>
    <citation>Zaaijer HL, ter Borg F, Cuypers HT, Hermus MC, Lelie PN. Comparison of methods for detection of hepatitis B virus DNA. J Clin Microbiol. 1994 Sep;32(9):2088-91.</citation>
    <PMID>7814529</PMID>
  </reference>
  <reference>
    <citation>Laras A, Koskinas J, Avgidis K, Hadziyannis SJ. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepat. 1998 Jul;5(4):241-8.</citation>
    <PMID>9751010</PMID>
  </reference>
  <reference>
    <citation>Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology. 1999 Mar;29(3):976-84.</citation>
    <PMID>10051506</PMID>
  </reference>
  <reference>
    <citation>Krajden M, Minor J, Cork L, Comanor L. Multi-measurement method comparison of three commercial hepatitis B virus DNA quantification assays. J Viral Hepat. 1998 Nov;5(6):415-22.</citation>
    <PMID>9857351</PMID>
  </reference>
  <reference>
    <citation>Lai VC, Guan R, Wood ML, Lo SK, Yuen MF, Lai CL. Nucleic acid-based cross-linking assay for detection and quantification of hepatitis B virus DNA. J Clin Microbiol. 1999 Jan;37(1):161-4.</citation>
    <PMID>9854083</PMID>
  </reference>
  <reference>
    <citation>Chan HLY, Leung NY, Lau TCM, Wong ML, Sung JJY. Comparison of three different hepatitis B virus (HBV) DNA assays in monitoring of anti-viral therapy. Hepatology 1999 (in press)</citation>
  </reference>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2006</study_first_submitted>
  <study_first_submitted_qc>June 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2006</study_first_posted>
  <last_update_submitted>October 27, 2006</last_update_submitted>
  <last_update_submitted_qc>October 27, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2006</last_update_posted>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>HBeAg negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

